VRTX · News · 20260821N
Guidance / Outlook
VERTEX PHARMACEUTICALS INC / MA · 2026-08-21 · Importance 75 · Surprise 60 · In source text
Vertex raised its full-year 2026 revenue guidance to US$13.1 billion–US$13.2 billion. The increase reflects continued cystic-fibrosis treatment demand and growing contributions from CASGEVY and JOURNAVX in sickle-cell disease, beta thalassemia, and acute pain. The updated outlook supports management’s diversification strategy beyond the cystic-fibrosis franchise, although reporting continues to flag concentration risk.
Key facts
- Vertex Pharmaceuticals increased its full-year 2026 revenue guidance to US$13.1 billion to US$13.2 billion. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Vertex Pharmaceuticals increased its full-year 2026 revenue guidance to US$13.1 billion to US$13.2 billion. |